Drugs / RevascorTM
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00927784 | Aug 2009 → May 2010 | heart failure | Icahn School of Medicine at Mount Sinai | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RevascorTM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00927784 ↗ |
| Known as | Mesenchymal Precursor cells | “Mesenchymal Precursor cells (RevascorTM)” NCT00927784 ↗ |
| Modality | Cell therapy | “injecting mesenchymal precursor cells (MPCs) into the heart” NCT00927784 ↗ |
| Route | Other | “Participants will receive intramyocardial injections of low dose (25 million) or higher dose (75 million) MPCs (in sequential cohorts).” NCT00927784 ↗ |